Molecular Designs Acquires Lamda Biotech
On September 25, Molecular Designs announced that it entered into an agreement to acquire Lamda Biotech. Lamda Biotech is a specialized provider of research products for application in molecular biology, functional genomics, proteomics and gene therapy. For more than 20 years, Lamda Biotech has been highly regarded for its offering of cutting-edge PCR products, RT-PCR reagents, RT-qPCR kits, Direct-PCR genotyping kits, DNA ladders, SafeStain and other protein and cell biology products. Molecular Designs is a team of doctors and scientists working to advance molecular diagnostics. It offers numerous multiplex PCR-based panels produced under GMP and ISO 13485:2016 quality... Read More »
Rafael Holdings Merges With Cyclo Therapeutics
Rafael Holdings, Inc. and Cyclo Therapeutics, Inc. announced that they have entered into a definitive merger agreement to combine the two companies to focus on the development of Trappsol® Cyclo™ for the treatment of Niemann-Pick Disease Type C1. The companies are building on a year-long history of strategic collaboration and investment. The merger involves Rafael Holdings issuing Class B common stock to Cyclo Therapeutics shareholders, valuing Cyclo shares at $0.95 each. In addition, the cash value will take into account the funding of Cyclo’s operations by Rafael with convertible notes through closing. Cyclo Therapeutics is a clinical-stage biotechnology company that focuses on the use... Read More »
Crown Laboratories Merges with Revance Therapeutics
Crown Laboratories, Inc., a portfolio company of New York City-based private equity firm Hildred Capital Partners LLC, announced that it entered into an agreement to acquire Revance Therapeutics, Inc. Crown will commence a tender offer to acquire all outstanding shares of Revance’s common stock for $6.66 per share in cash, representing a total enterprise value of $924 million. The purchase price represents a premium of 89% over Revance’s closing market price on August 9, 2024, and a 111% premium to Revance’s 60-day volume-weighted average price. Revance Therapeutics, Inc. is a biotechnology company based in Nashville, Tennessee. Revance’s... Read More »
Boehringer Ingelheim Acquires Nerio Therapeutics for $1.3 Billion
Boehringer Ingelheim announced on July 29 that it will buy Nerio Therapeutics for $1.3 billion. With the purchase of Nerio Therapeutics, Boehringer Ingelheim is also picking up a preclinical immune checkpoint inhibitor program that it hopes will become the “centerpiece” of its immune-oncology portfolio. Nerio Therapeutics is a biotechnology company focused on the life sciences sector. It was founded in 2019 and is based in La Jolla, California. Nerio has been working on small molecules that inhibit protein tyrosine phosphatases N1 and N2 (PTPN1 and PTPN2). PTPN1 and PTPN2 regulate cytokine signaling and T cell receptor signaling, with preclinical research suggesting inhibiting them can... Read More »
Lilly Acquires Morphic Holding, Inc. for $3.2 Billion
On July 8, Lilly (formally known as Eli Lilly and Company) announced that it acquired Morphic Holding, Inc. for an estimated $3.2 billion. Lilly plans to acquire all outstanding shares of Morphic for $57 per share in cash. The purchase price at closing is a premium of around 79% to the closing stock price on Friday. Morphic Holding is a Massachusetts-based biotechnology company that is leading the development of new oral integrin drugs for inflammatory bowel diseases. Its proprietary MInT drug discovery platform combines an expert understanding of integrin dynamics and analytical capabilities with foundational structural biology insights and ongoing input from the Massachusetts-based... Read More »Schedule a demo
Gain access to the best healthcare and long-term care investment intelligence, data, and analysis.
